

Specimen Collected: 1/29/2025 11:20 MST

Neuronal Antibody IgG, Immunoblot, Ser | Received: 1/29/2025 11:20 MST Report/Verified: 1/29/2025 12:19 MST

Procedure	Result	Units	Reference Interval
Neuronal Nuclear Ab (Hu) IgG, IB, Serum	Low Positive * f1 i1		[Negative]
Neuronal Nuclear Ab (Ri) IgG, IB, Serum	Positive * i2		[Negative]
Purkinje Cell Ab (Yo) IgG, IB, Ser	High Positive * i3		[Negative]
Purkinje Cell Ab (TR/DNER) IgG, IB, Ser	Positive * i4		[Negative]

Paraneoplastic Abs (PCCA/ANNA) Rflx Scrn | Received: 1/29/2025 11:20 MST Report/Verified: 1/29/2025 12:19 MST

Procedure	Result	Units	Reference Interval
Purkinje Cell/Neuronal Nuclear IgG Scrn	PCCA Detected * f2 i5		[None Detected]

Purkinje Cell Ab Titer, IgG | Received: 1/29/2025 11:20 MST Report/Verified: 1/29/2025 12:19 MST

Procedure	Result	Units	Reference Interval
Purkinje Cell Antibody Titer IgG	1:80 * i6		<1:10]

**Result Footnote**

f1: Neuronal Nuclear Ab (Hu) IgG, IB, Serum

Low positive reactivity to Hu detected. Strong clinical correlation is recommended.

f2: Purkinje Cell/Neuronal Nuclear IgG Scrn

Antibodies detected, therefore IFA titer and Immunoblot testing to be performed.

**Test Information**

i1: Neuronal Nuclear Ab (Hu) IgG, IB, Serum

INTERPRETIVE INFORMATION: Neuronal Nuclear Ab IgG, Immunoblot, Ser

This test detects IgG antineuronal antibodies to Hu, Ri, Yo and Tr (DNER) antigens.

Antineuronal antibodies serve as markers that aid in discriminating between a true paraneoplastic neurological disorder (PND) and other inflammatory disorders of the nervous system. Anti-Hu (antineuronal nuclear antibody, type I) is associated with small-cell lung cancer. Anti-Ri (antineuronal nuclear antibody, type II) is associated with neuroblastoma in children and with fallopian tube and breast cancer in adults. Anti-Yo (anti-Purkinje cell cytoplasmic antibody) is associated with ovarian and breast cancer. Anti-Tr(DNER) is associated with Hodgkin's lymphoma.

The presence of one or more of these antineuronal antibodies detected by both immunoblot (IB) and immunofluorescence (IFA) supports a clinical diagnosis of PND and should lead to a focused search for the underlying neoplasm. A positive IB result but negative IFA result is of questionable clinical significance. Thus, strong clinical correlation is recommended.

\* = Abnormal, # = Corrected, C = Critical, f = Result Footnote, H = High, i = Test Information, L = Low, t = Interpretive Text, @ = Performing lab

**Unless otherwise indicated, testing performed at:****ARUP Laboratories**

500 Chipeta Way, Salt Lake City, UT 84108

Laboratory Director: Jonathan R. Genzen, MD, PhD

**ARUP Accession:** 25-029-900096**Report Request ID:** 20283676**Printed:** 2/5/2025 10:34 MST

Page 1 of 2

**Test Information**

i1: Neuronal Nuclear Ab (Hu) IgG, IB, Serum

This test was developed and its performance characteristics determined by ARUP Laboratories. It has not been cleared or approved by the US Food and Drug Administration. This test was performed in a CLIA certified laboratory and is intended for clinical purposes.

i2: Neuronal Nuclear Ab (Ri) IgG, IB, Serum

INTERPRETIVE INFORMATION: Neuronal Nuclear Ab (Ri) IgG, IB, Serum

This test was developed and its performance characteristics determined by ARUP Laboratories. It has not been cleared or approved by the US Food and Drug Administration. This test was performed in a CLIA certified laboratory and is intended for clinical purposes.

i3: Purkinje Cell Ab (Yo) IgG, IB, Ser

INTERPRETIVE INFORMATION: Purkinje Cell Ab (Yo) IgG, IB, Ser

This test was developed and its performance characteristics determined by ARUP Laboratories. It has not been cleared or approved by the US Food and Drug Administration. This test was performed in a CLIA certified laboratory and is intended for clinical purposes.

i4: Purkinje Cell Ab (TR/DNER) IgG, IB, Ser

INTERPRETIVE INFORMATION: Purkinje Cell Ab (TR/DNER) IgG, IB, Ser

This test was developed and its performance characteristics determined by ARUP Laboratories. It has not been cleared or approved by the US Food and Drug Administration. This test was performed in a CLIA certified laboratory and is intended for clinical purposes.

i5: Purkinje Cell/Neuronal Nuclear IgG Scrn

INTERPRETIVE INFORMATION: Purkinje Cell/Neuronal Nuclear IgG Scrn

This test was developed and its performance characteristics determined by ARUP Laboratories. It has not been cleared or approved by the US Food and Drug Administration. This test was performed in a CLIA certified laboratory and is intended for clinical purposes.

i6: Purkinje Cell Antibody Titer IgG

INTERPRETIVE INFORMATION: Purkinje Cell Ab Titer, IgG

This test was developed and its performance characteristics determined by ARUP Laboratories. It has not been cleared or approved by the US Food and Drug Administration. This test was performed in a CLIA certified laboratory and is intended for clinical purposes.

\*=Abnormal, #=Corrected, C=Critical, f=Result Footnote, H-High, i-Test Information, L-Low, t-Interpretive Text, @=Performing lab

**Unless otherwise indicated, testing performed at:**

**ARUP Laboratories**

500 Chipeta Way, Salt Lake City, UT 84108

Laboratory Director: Jonathan R. Genzen, MD, PhD

**ARUP Accession:** 25-029-900096

**Report Request ID:** 20283676

**Printed:** 2/5/2025 10:34 MST

Page 2 of 2